公开(公告)号：EP0986581A1

公开(公告)日：2000-03-22

申请号：EP98925356.2

申请日：1998-06-05

申请人： HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC.

发明人： WEITZ, Jeffrey ,  HIRSH, Jack

IPC分类号： C08B37/10 ,  A61K31/725

CPC分类号： C08B37/0078 ,  A61K31/727 ,  Y10S514/921

摘要： The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

公开(公告)号：EP0738156A1

公开(公告)日：1996-10-23

申请号：EP95904993.0

申请日：1994-12-22

申请人： Hamilton Civic Hospitals Research Development, Inc.

发明人： WEITZ, Jeffrey I. ,  HIRSH, Jack

IPC分类号： C12N9 ,  A61K38 ,  A61K39 ,  A61P7 ,  A61P9 ,  A61P43 ,  C07K14 ,  C07K16

CPC分类号： C12N9/6429 ,  A61K38/363 ,  A61K38/4833 ,  C07K14/75 ,  C07K14/811 ,  C07K16/36 ,  C07K16/40 ,  C12Y304/21005

摘要： Thrombus or clot formation and accretion are inhibited by administering thrombin-displacing substances to a patient. The thrombin-displacing substances comprise either thrombin analogs which bind to the thrombin-binding site on fibrin or fibrin analogs which bind to a fibrin-binding site on thrombin. By displacing the thrombin from clot or thrombus, the thrombin is released into circulation where it is inactivated by endogenous anti-proteinases. The fibrin analogs which bind to the fibrin-binding site on thrombin may be linked to a second binding moiety which binds to and/or inactivates the catalytic site and/or exosite I on thrombin to further inhibit thrombosis. The ability of test substances to displace thrombin is measured by exposure of the substance to immobilized thrombin-fibrin complex.

公开(公告)号：EP1663299A2

公开(公告)日：2006-06-07

申请号：EP04761661.0

申请日：2004-08-12

申请人： HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC.

发明人： CHAN, Anthony, Kam, Chuen ,  KLEMENT, Petr ,  TRESSEL, Paul ,  BERRY, Leslie, Roy ,  WEITZ, Jeffrey, I. ,  HIRSH, Jack

IPC分类号： A61K38/55 ,  A61K31/726 ,  A61K31/727 ,  A61P7/02 ,  A61P9/10

CPC分类号： A61K31/726 ,  A61K38/57 ,  A61K47/61 ,  A61K2300/00

摘要： The present invention relates to therapeutic methods for preventing or reducing neurological events utilizing a glycosaminoglycan and a serpin, including complexes and conjugates thereof. Methods of the present invention may be advantageous for preventing or reducing neurological events prior to, or during medical or surgical procedures, and after a neurological event. In particular, the present invention deals with neurological events associated with the generation of emboli that can lodge in the brain and/or cerebral circulation during cardiac surgery.

公开(公告)号：EP1192187A1

公开(公告)日：2002-04-03

申请号：EP00941847.6

申请日：2000-06-29

申请人： HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC.

发明人： WEITZ, Jeffrey, I. ,  HIRSH, Jack

IPC分类号： C08B37/10 ,  A61K31/727

CPC分类号： C08B37/0078 ,  A61K31/715 ,  A61K31/727 ,  A61K45/06

摘要： The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infraction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

公开(公告)号：EP0879298A2

公开(公告)日：1998-11-25

申请号：EP97900005.0

申请日：1997-01-02

申请人： HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC.

发明人： AUSTIN, Richard, C. ,  HIRSH, Jack ,  WEITZ, Jeff

IPC分类号： C12N15 ,  A61K31 ,  A61P9 ,  C12Q1 ,  G01N33 ,  G01N37

CPC分类号： C12Q1/6809 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/226

摘要： A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

公开(公告)号：EP0820314A1

公开(公告)日：1998-01-28

申请号：EP96908962.0

申请日：1996-04-09

申请人： HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC.

发明人： HIRSH, Jack ,  JOHNSTON, Marilyn ,  TEOH, Kevin

IPC分类号： A61L24 ,  A61K38 ,  C12N9

CPC分类号： C12N9/6429 ,  A61L24/106 ,  C12Y304/21005

摘要： A fibrin glue includes a fibrinogen component and a thrombin component, both prepared from single donor plasma. The plasma is precipitated to produce a precipitate containing fibrinogen and a supernatant containing the thrombin. The precipitate may be resuspended in a small volume of supernatant and used as the fibrinogen component. The supernatant is further treated by clotting to convert residual fibrinogen to fibrin and filtration to remove the fibrin. Optionally, at least a portion of the anti-thrombin III originally present in the supernatant may be removed to prolong thrombin activity therein. The resulting serum can be used as the thrombin component.